sclerosing cholangitis: A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.
Cholangitis (primary sclerosing, PSC), with reimbursement 202
DOID EFO Endpoint Browser PheWeb
K11_CHOLANGI_STRICT
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditions
|
26974 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
602 |
4. Check minimum number of eventsNone |
602 |
5. Include endpointsNone |
602 |
6. Filter based on genotype QC (FinnGen only) |
585 |
Control definitions (FinnGen only)
Control exclude
K11_IBD_STRICT_PSC
Control conditions
not K11_REIMB_202
Extra metadata
First used in FinnGen datafreeze
DF3
Parent code in ICD-10
K83
Name in latin
Cholangitis
Similar endpoints
↥List of similar endpoints to
Cholangitis (primary sclerosing, PSC), with reimbursement 202
based on the number of shared cases.
Similar with more cases:
- Cholangitis (primary sclerosing, PSC)
- KELA_REIMBURSEMENT_202
- Disorders of gallbladder, biliary tract and pancreas
- Gastrointestinal diseases
- Any reimbursement code in KELA
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2699 | 1491 | 1192 |
| Only index persons | 2473 | 1364 | 1109 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 52.12 | 57.80 | 44.91 |
| Only index persons | 50.38 | 56.59 | 42.74 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 585 | 325 | 260 |
| Unadjusted period prevalence (%) | 0.13 | 0.13 | 0.13 |
| Median age at first event (years) | 44.98 | 48.72 | 40.30 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint K11_CHOLANGI_STRICT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| K11_CHOLANGI_STRICT | 2.908 [2.29, 3.7] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.435 |
During the follow-up period (1.1.1998 — 31.12.2019), 280 out of 1127 females with K11_CHOLANGI_STRICT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| K11_CHOLANGI_STRICT | 2.237 [1.71, 2.93] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 180 out of 971 males with K11_CHOLANGI_STRICT died.
Mortality risk
Mortality risk for people of age
years, who have K11_CHOLANGI_STRICT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.293% | 0.479% |
| 5 | 1.856% | 2.601% |
| 10 | 4.805% | 6.542% |
| 15 | 8.555% | 12.088% |
| 20 | 14.957% | 19.247% |
Relationships between endpoints
↥Index endpoint: K11_CHOLANGI_STRICT – Cholangitis (primary sclerosing, PSC), with reimbursement 202
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data